We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
MedicalSystem

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Novel Microfluidic qDBS-Sampling Technology Could Find Broader Use in Clinical Diagnosis

By LabMedica International staff writers
Posted on 07 Oct 2022
Print article
Image: Capitainer B card’s microfluidic qDBS technology provides exact sample volume to a pre-cut DBS disc (Photo courtesy of Capitainer)
Image: Capitainer B card’s microfluidic qDBS technology provides exact sample volume to a pre-cut DBS disc (Photo courtesy of Capitainer)

Dried blood spot (DBS) sampling has been used since the 1960s when introduced in newborn screening. However, a major drawback of conventional DBS cards is the lack of volumetric control and the hematocrit (Ht) effect. As a different Ht, due to different blood viscosity, leads to different spot size a standardized subpunch on conventional DBS does still not provide an exact volume. These limitations reduce conventional DBS to qualitative or semi-quantitative analysis, while most clinical tests are quantitative. To counter this challenge, a novel microfluidic quantitative DBS (qDBS) technology provides an exact sample volume to a pre-cut DBS disc. Since the full volume defined spot is used for analysis, the Ht effect is overcome and the microsample can be used for quantitative tests. Now, a new collaboration aims to accelerate method development for the implementation of a novel microfluidic qDBS-sampling based technology for clinical diagnostics in the US and globally.

Capitainer AB (Solna, Sweden) has entered a collaboration agreement with Timothy J. Garrett Laboratory, College of Medicine, University of Florida (Gainesville, FL, USA) to accelerate method development and pave the way for broader use of the company’s qDBS technology in clinical diagnosis. Capitainer has developed qDBS technology, a microfluidsystem-based technology that offers a solution for easy and accurate self sampling. Capitainer’s blood sampling cards are built on its qDBS technology. It uses a combination of paper and polymer microfluidics to meter a 10 µl fixed volume from an undefined volume of finger prick blood. After applying a drop of blood to the inlet, a metering channel in the device is automatically filled. A valve composed of a thin dissolvable membrane then opens up and removes excessive blood at the inlet. Subsequently, a second membrane opens up, allowing for transfer of the metered blood volume onto the sample collection disk. The sample is allowed to dry forming a high quality DBS sample suitable for quantitative analysis.

Capitainer's qDBS-sampling technology has been validated in real world population studies. No less than 97% of the cards sent back by regular mail to the lab met the approved quality standard for analysis. Additionally, a major study on the advantages of volumetric microsampling DBS devices in monitoring patients with phenylketonuria (PKU), demonstrated conclusively the superiority of Capitainer's solution over conventional cards and competition. Capitainer has been shown to have a superior product for self-sampling with excellent usability and volumetric accuracy and precision. However, there is a shortage of clinical laboratories and methods for microsamples collected at home, and the collaboration will accelerate development of necessary laboratory tools.

"I'm excited about developing precision diagnostics that will enable future health care and look forward to this collaborative effort," said Dr. Timothy Garrett, an associate professor in the university's Department of Pathology, Immunology and Laboratory Medicine. "Our success would mean a changed landscape for medical diagnostics."

"Now we can together develop new clinical analysis in areas of screening, diagnostics and metabolomics research starting at the 1st Step. A new, improved, more precise, protected dried blood spot," said Dr. Donald H. Chace, Capitainer's North America representative who will also add his vast experience in dried blood spot analysis, covering neonatology, clinical chemistry, newborn screening, mass spectrometry and forensic science. This combined with Garrett's access to a network of clinics for collaboration will, Capitainer believes, create the ideal foundation for new testing method development and validation.

Related Links:
Capitainer AB 
University of Florida 

Gold Supplier
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
New
Portable Electrolyte Analyzer
XI-951
New
DNA/RNA Extraction Buffer
Enzymatic DNA/RNA Extraction Buffer
New
POC Analyzer
abioSCOPE

Print article
SUGENTECH INC.

Channels

Clinical Chem.

view channel
Image: Equivalence of Genetically Elevated LDL and Lipoprotein(a) on Myocardial Infarction (Photo courtesy of Viborg Regional Hospital)

Familial Hypercholesterolemia Patients With ACD Have Elevated Lipoprotein(a)

Familial hypercholesterolemia (FH) is a genetic disorder characterized by high cholesterol levels, specifically very high levels of low-density lipoprotein (LDL cholesterol), in the blood and early cardiovascular... Read more

Molecular Diagnostics

view channel
Image: A cheap blood test could improve diagnosis of myocarditis (Photo courtesy of Queen Mary University of London)

First-Ever Blood Test Could Detect Deadly Heart Inflammation Within Hours

Myocarditis, or inflammation of the heart muscle, is a difficult condition to diagnose. Symptoms include a temperature, fatigue, chest pain and shortness of breath, which can all be easily mistaken for... Read more

Microbiology

view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more

Industry

view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.